Inflammatory Bowel Drugs To Go Head-To-Head With PCORI Funding
Executive Summary
A number of drug-related comparative effectiveness research projects are approved for PCORI-sponsored research in its second funding cycle. Health IT-related projects also get attention as the institute spends more than $88 million on 51 projects.
You may also be interested in...
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.
Antibiotics Go Head-To-Head In PCORI-Funded Observational Study
Patient-Centered Outcomes Research Institute selected five drug-related research topics for funding, including a look at narrow- versus broad-spectrum antibiotics for acute respiratory tract infections in children, though all studies are observational. PCORI approved 52 CER projects in this third funding round, including many declined in the first round.
Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease
Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.